| Date Filed | Type | Description |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/17/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/28/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/04/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/03/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/03/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/15/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/08/2022 |
8-K
| Quarterly results |
| 02/02/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"About IONIQ Sciences, Inc. IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics or bioimpedance technology and Artificial Intelligence . IONIQ Science’ s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. For further information about IONIQ Sciences, Inc., please contact: Andy Robertson | 1-801-736-0729 | [email protected] IONIQ Sciences, Vice President of Business Development IONIQ Sciences, Inc. 350 W. 800 N., Suite 214 S..." |
|
| 11/12/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 10/07/2021 |
8-K
| Appointed a new director|
Docs:
|
"IONIQ Sciences Announces the Appointment of Aaron B. Dorny to its Board of Directors Salt Lake City, UT, October 7, 2021 – IONIQ Sciences, Inc. , is developing a rapid and non-invasive Multi-Cancer Screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today IONIQ Sciences announced the appointment of Aaron B. Dorny to its Board of Directors. Mr. Jared Bauer, CEO, stated, “On behalf of the IONIQ Sciences Board of Directors, we are delighted to welcome Mr. Dorny to the Board. We believe that his deep understanding of our life science business and proven financial acumen with companies large and small will greatly help us achieve our goals. Mr. Dorny’ s contributions to our company over the pas..." |
|
| 08/16/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/14/2021 |
8-K
| Quarterly results |
| 06/02/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/28/2021 |
8-K
| Quarterly results |
| 05/25/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/25/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 05/24/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/14/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 05/03/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 04/20/2021 |
GN
| Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021 |
| 03/15/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 12/21/2020 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 12/08/2020 |
GN
| Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth |
| 11/30/2020 |
GN
| Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD |
| 11/03/2020 |
GN
| Pulmonx to Present at Upcoming Investor Conferences |
| 11/02/2020 |
GN
| Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD) |
| 10/05/2020 |
GN
| Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares |
| 09/30/2020 |
GN
| Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering |
| 09/16/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
|